| Subject: | FDA Reports of Side Effects with Diprivan (propofol) Use |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 18 Jun 2007 - 11:00 am |
| The FDA is informing healthcare professionals about several clusters of patients who have experienced chills, fever, and body aches shortly after receiving propofol for sedation or general anesthesia. Multiple vials and several lots of propofol used in patients who experienced these symptoms were tested and there was no evidence that the propofol vials or pre-filled syringes used were contaminated with bacteria or endotoxins. To minimize the potential for bacterial contamination, propofol vials... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. The StayAlert! system was designed by healthcare professionals actively working in the healthcare environment, who were faced with attempting to competently provide quality care and services while "doing more with less". StayAlert! provides the answer to efficiently performing a variety of required job components from one centralized virtual location. StayAlert! improves data sharing and communications, thus reducing cost, broadening access and providing a system of documentation and follow-up. |
|